{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:39:15Z","timestamp":1792805955720,"version":"4.5.0"},"reference-count":245,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,11,1]],"date-time":"2024-11-01T00:00:00Z","timestamp":1730419200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The French Journal of Urology"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1016\/j.fjurol.2024.102710","type":"journal-article","created":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T22:57:42Z","timestamp":1732229862000},"page":"102710","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["French AFU Cancer Committee Guidelines\u00a0\u2013\u00a0Update 2024\u20132026: Prostate cancer\u00a0\u2013\u00a0Management of metastatic disease and castration resistance"],"prefix":"10.1016","volume":"34","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6004-2152","authenticated-orcid":false,"given":"Guillaume","family":"Ploussard","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9573-2938","authenticated-orcid":false,"given":"Charles","family":"Dariane","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Romain","family":"Mathieu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Micha\u00ebl","family":"Baboudjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Barret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Brureau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3049-5318","authenticated-orcid":false,"given":"Ga\u00eblle","family":"Fiard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ga\u00eblle","family":"Fromont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5409-2911","authenticated-orcid":false,"given":"Jonathan","family":"Olivier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Rozet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1158-0082","authenticated-orcid":false,"given":"Arthur","family":"Peyrottes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rapha\u00eble","family":"Renard-Penna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Sargos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Supiot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L\u00e9a","family":"Turpin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guilhem","family":"Roubaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morgan","family":"Roupr\u00eat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.fjurol.2024.102710_bib1000","first-page":"1058","volume":"104","author":"Blana","year":"2009","journal-title":"High-intensity focused ultrasound for prostate cancer: comparative definitions of biochemical failure. BJU Int"},{"issue":"5","key":"10.1016\/j.fjurol.2024.102710_bib1005","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/0090-4295(94)90180-5","article-title":"Evaluation of serum prostate-specific antigen velocity after radical prostatectomy to distinguish local recurrence from distant metastases","volume":"43","author":"Partin","year":"1994","journal-title":"Urology"},{"issue":"6","key":"10.1016\/j.fjurol.2024.102710_bib1010","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1016\/j.eururo.2018.10.011","article-title":"Prognostic value of biochemical recurrence following treatment with curative intent for prostate cancer: a systematic review","volume":"75","author":"Van den Broeck","year":"2019","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.fjurol.2024.102710_bib1015","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1016\/j.euo.2021.01.003","article-title":"Prostate magnetic resonance imaging for local recurrence reporting (PI-RR): international consensus-based guidelines on multiparametric magnetic resonance imaging for prostate cancer recurrence after radiation therapy and radical prostatectomy","volume":"4","author":"Panebianco","year":"2021","journal-title":"Eur Urol Oncol"},{"issue":"3","key":"10.1016\/j.fjurol.2024.102710_bib1020","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/j.purol.2014.12.002","article-title":"[Imagery of treated prostate cancer]","volume":"25","author":"Renard-Penna","year":"2015","journal-title":"Prog Urol"},{"issue":"5","key":"10.1016\/j.fjurol.2024.102710_bib1025","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/j.ijrobp.2010.07.1975","article-title":"Long-term results after high-dose radiotherapy and adjuvant hormones in prostate cancer: how curable is high-risk disease?","volume":"81","author":"Zapatero","year":"2011","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"10.1016\/j.fjurol.2024.102710_bib1030","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.eururo.2019.01.049","volume":"77","author":"Perera","year":"2020","journal-title":"Eur Urol"},{"issue":"7","key":"10.1016\/j.fjurol.2024.102710_bib1035","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.3390\/cancers13071594","article-title":"Restaging the biochemical recurrence of prostate cancer with [(68)Ga]Ga-PSMA-11 PET\/CT: diagnostic performance and impact on patient disease management","volume":"13","author":"Fourquet","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"11","key":"10.1016\/j.fjurol.2024.102710_bib1040","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.2967\/jnumed.119.226381","article-title":"A Prospective study on (18)F-DCFPyL PSMA PET\/CT imaging in biochemical recurrence of prostate cancer","volume":"60","author":"Rousseau","year":"2019","journal-title":"J Nucl Med"},{"issue":"12","key":"10.1016\/j.fjurol.2024.102710_bib1045","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1097\/MNM.0000000000001770","article-title":"Comparison of 18F-PSMA-1007 and 18F-Choline PET\/CT in prostate cancer patients with biochemical recurrence: a phase 3, prospective, multicenter, randomized study","volume":"44","author":"Panagiotidis","year":"2023","journal-title":"Nucl Med Commun"},{"issue":"6","key":"10.1016\/j.fjurol.2024.102710_bib1050","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/jamaoncol.2019.0096","article-title":"Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: a prospective single-arm clinical trial","volume":"5","author":"Fendler","year":"2019","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.fjurol.2024.102710_bib1055","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.ijrobp.2020.01.050","article-title":"Effect of (18)F-Fluciclovine positron emission tomography on the management of patients with recurrence of prostate cancer: results from the FALCON Trial","volume":"107","author":"Scarsbrook","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"10288","key":"10.1016\/j.fjurol.2024.102710_bib1060","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1016\/S0140-6736(21)00581-X","article-title":"(18)F-fluciclovine-PET\/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre, open-label, phase 2\/3 randomised controlled trial","volume":"397","author":"Jani","year":"2021","journal-title":"Lancet"},{"issue":"9","key":"10.1016\/j.fjurol.2024.102710_bib1065","doi-asserted-by":"crossref","first-page":"1286","DOI":"10.1016\/S1470-2045(19)30415-2","article-title":"(18)F-fluciclovine PET-CT and (68)Ga-PSMA-11 PET-CT in patients with early biochemical recurrence after prostatectomy: a prospective, single-centre, single-arm, comparative imaging trial","volume":"20","author":"Calais","year":"2019","journal-title":"Lancet Oncol"},{"issue":"9858","key":"10.1016\/j.fjurol.2024.102710_bib1070","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/S0140-6736(12)61253-7","article-title":"Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911)","volume":"380","author":"Bolla","year":"2012","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.fjurol.2024.102710_bib1075","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/j.juro.2008.11.032","article-title":"Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term follow-up of a randomized clinical trial","volume":"181","author":"Thompson","year":"2009","journal-title":"J Urol"},{"issue":"2","key":"10.1016\/j.fjurol.2024.102710_bib1080","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.eururo.2014.03.011","article-title":"Adjuvant radiotherapy versus wait-and-see after radical prostatectomy: 10-year follow-up of the ARO 96-02\/AUO AP 09\/95 trial","volume":"66","author":"Wiegel","year":"2014","journal-title":"Eur Urol"},{"issue":"10","key":"10.1016\/j.fjurol.2024.102710_bib1085","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1016\/S1470-2045(20)30454-X","article-title":"Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial","volume":"21","author":"Sargos","year":"2020","journal-title":"Lancet Oncol"},{"issue":"10260","key":"10.1016\/j.fjurol.2024.102710_bib1090","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1016\/S0140-6736(20)31553-1","article-title":"Timing of radiotherapy after radical prostatectomy (RADICALS-RT): a randomised, controlled phase 3 trial","volume":"396","author":"Parker","year":"2020","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.fjurol.2024.102710_bib1095","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/S1470-2045(20)30456-3","article-title":"Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03\/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial","volume":"21","author":"Kneebone","year":"2020","journal-title":"Lancet Oncol"},{"issue":"10260","key":"10.1016\/j.fjurol.2024.102710_bib1100","doi-asserted-by":"crossref","first-page":"1422","DOI":"10.1016\/S0140-6736(20)31952-8","article-title":"Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data","volume":"396","author":"Vale","year":"2020","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.fjurol.2024.102710_bib1105","doi-asserted-by":"crossref","first-page":"2284","DOI":"10.1200\/JCO.20.03714","article-title":"Adjuvant versus early salvage radiation therapy for men at high risk for recurrence following radical prostatectomy for prostate cancer and the risk of death","volume":"39","author":"Tilki","year":"2021","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.fjurol.2024.102710_bib1110","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1016\/j.annonc.2024.03.010","article-title":"Timing of radiotherapy (RT) after radical prostatectomy (RP): long-term outcomes in the RADICALS-RT trial (NCT00541047)","volume":"35","author":"Parker","year":"2024","journal-title":"Ann Oncol"},{"issue":"32","key":"10.1016\/j.fjurol.2024.102710_bib1115","doi-asserted-by":"crossref","first-page":"3864","DOI":"10.1200\/JCO.2016.68.3425","article-title":"Improved metastasis-free and survival outcomes with early salvage radiotherapy in men with detectable prostate-specific antigen after prostatectomy for prostate cancer","volume":"34","author":"Stish","year":"2016","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.1016\/j.fjurol.2024.102710_bib1120","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.eururo.2020.11.021","article-title":"A systematic review of the evidence for the Decipher genomic classifier in prostate cancer","volume":"79","author":"Jairath","year":"2021","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.fjurol.2024.102710_bib1125","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.ctrv.2008.08.002","article-title":"A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma","volume":"35","author":"Shelley","year":"2009","journal-title":"Cancer Treat Rev"},{"issue":"6","key":"10.1016\/j.fjurol.2024.102710_bib1130","doi-asserted-by":"crossref","first-page":"472","DOI":"10.1016\/S1470-2045(06)70700-8","article-title":"Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy","volume":"7","author":"Messing","year":"2006","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.fjurol.2024.102710_bib1135","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/j.eururo.2008.09.043","volume":"55","author":"Briganti","year":"2009","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.fjurol.2024.102710_bib1140","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.eururo.2009.12.034","article-title":"Survival benefit of radical prostatectomy in lymph node-positive patients with prostate cancer","volume":"57","author":"Engel","year":"2010","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.fjurol.2024.102710_bib1145","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.euo.2020.08.005","article-title":"Management of patients with node-positive prostate cancer at radical prostatectomy and pelvic lymph node dissection: a systematic review","volume":"3","author":"Marra","year":"2020","journal-title":"Eur Urol Oncol"},{"issue":"35","key":"10.1016\/j.fjurol.2024.102710_bib1150","doi-asserted-by":"crossref","first-page":"3939","DOI":"10.1200\/JCO.2013.54.7893","article-title":"Impact of adjuvant radiotherapy on survival of patients with node-positive prostate cancer","volume":"32","author":"Abdollah","year":"2014","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.fjurol.2024.102710_bib1155","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.euo.2021.01.001","article-title":"Management of persistently elevated prostate-specific antigen after radical prostatectomy: a systematic review of the literature","volume":"4","author":"Ploussard","year":"2021","journal-title":"Eur Urol Oncol"},{"issue":"1","key":"10.1016\/j.fjurol.2024.102710_bib1160","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/j.urology.2008.07.067","article-title":"Does benign prostatic tissue contribute to measurable PSA levels after radical prostatectomy?","volume":"74","author":"Godoy","year":"2009","journal-title":"Urology"},{"issue":"1","key":"10.1016\/j.fjurol.2024.102710_bib1165","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.eururo.2019.01.048","article-title":"Persistent prostate-specific antigen after radical prostatectomy and its impact on oncologic outcomes","volume":"76","author":"Preisser","year":"2019","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.fjurol.2024.102710_bib1170","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1007\/s00345-013-1214-0","article-title":"Clinical outcomes after salvage radiotherapy without androgen deprivation therapy in patients with persistently detectable PSA after radical prostatectomy: results from a national multicentre study","volume":"32","author":"Ploussard","year":"2014","journal-title":"World J Urol"},{"issue":"4","key":"10.1016\/j.fjurol.2024.102710_bib1175","doi-asserted-by":"crossref","first-page":"e87","DOI":"10.1016\/j.eururo.2022.01.012","article-title":"Restaging of patients with persistently elevated prostate-specific antigen after radical prostatectomy using [(68)Ga]-PSMA-11 positron emission tomography\/computed tomography: impact on disease management","volume":"81","author":"Gauthe","year":"2022","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.fjurol.2024.102710_bib1180","doi-asserted-by":"crossref","first-page":"1034","DOI":"10.1016\/j.eururo.2013.08.013","article-title":"Early salvage radiotherapy following radical prostatectomy","volume":"65","author":"Pfister","year":"2014","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.fjurol.2024.102710_bib1185","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.eururo.2019.11.023","article-title":"Salvage radiotherapy versus hormone therapy for prostate-specific antigen failure after radical prostatectomy: a randomised, multicentre, open-LABEL, phase 3 trial (JCOG0401)(dagger)","volume":"77","author":"Yokomizo","year":"2020","journal-title":"Eur Urol"},{"issue":"13","key":"10.1016\/j.fjurol.2024.102710_bib1190","doi-asserted-by":"crossref","first-page":"2428","DOI":"10.1200\/JCO.22.02489","article-title":"Prostate-specific antigen level at the time of salvage therapy after radical prostatectomy for prostate cancer and the risk of death","volume":"41","author":"Tilki","year":"2023","journal-title":"J Clin Oncol"},{"issue":"10338","key":"10.1016\/j.fjurol.2024.102710_bib1195","doi-asserted-by":"crossref","first-page":"1886","DOI":"10.1016\/S0140-6736(21)01790-6","article-title":"The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology\/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial","volume":"399","author":"Pollack","year":"2022","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.fjurol.2024.102710_bib1200","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1001\/jamaoncol.2023.7291","article-title":"Noninferiority of hypofractionated vs. conventional postprostatectomy radiotherapy for genitourinary and gastrointestinal symptoms: the NRG-GU003 Phase 3 randomized clinical trial","volume":"10","author":"Buyyounouski","year":"2024","journal-title":"JAMA Oncol"},{"issue":"3","key":"10.1016\/j.fjurol.2024.102710_bib1205","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.eururo.2021.05.033","article-title":"Dose-intensified versus conventional-dose salvage radiotherapy for biochemically recurrent prostate cancer after prostatectomy: the SAKK 09\/10 Randomized Phase 3 Trial","volume":"80","author":"Ghadjar","year":"2021","journal-title":"Eur Urol"},{"issue":"2","key":"10.1016\/j.fjurol.2024.102710_bib1210","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1016\/j.ijrobp.2019.09.047","article-title":"Toxicity and biochemical outcomes of dose-intensified postoperative radiation therapy for prostate cancer: results of a Randomized Phase III Trial","volume":"106","author":"Qi","year":"2020","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"10.1016\/j.fjurol.2024.102710_bib1215","doi-asserted-by":"crossref","first-page":"1243","DOI":"10.1016\/j.ijrobp.2020.11.010","article-title":"Prostate bed delineation guidelines for postoperative radiation therapy: on behalf of the Francophone Group of Urological Radiation Therapy","volume":"109","author":"Robin","year":"2021","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.fjurol.2024.102710_bib1220","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ijrobp.2023.07.020","article-title":"Consensus delineation guidelines for pelvic lymph node radiation therapy of prostate cancer: on behalf of the Francophone Group of Urological Radiation Therapy (GFRU)","volume":"118","author":"De Hertogh","year":"2024","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"10.1016\/j.fjurol.2024.102710_bib1225","doi-asserted-by":"crossref","first-page":"82","DOI":"10.2967\/jnumed.117.197160","article-title":"The impact of (68)Ga-PSMA PET\/CT on management intent in prostate cancer: results of an Australian prospective multicenter study","volume":"59","author":"Roach","year":"2018","journal-title":"J Nucl Med"},{"issue":"13","key":"10.1016\/j.fjurol.2024.102710_bib1230","doi-asserted-by":"crossref","first-page":"3674","DOI":"10.1158\/1078-0432.CCR-20-4573","article-title":"Diagnostic performance of (18)F-DCFPyL-PET\/CT in men with biochemically recurrent prostate cancer: results from the CONDOR Phase III, multicenter study","volume":"27","author":"Morris","year":"2021","journal-title":"Clin Cancer Res"},{"issue":"11","key":"10.1016\/j.fjurol.2024.102710_bib1235","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1007\/s00259-023-06301-5","article-title":"[(18)F]DCFPyL PET\/CT versus [(18)F]fluoromethylcholine PET\/CT in biochemical recurrence of prostate cancer (PYTHON): a prospective, open label, cross-over, comparative study","volume":"50","author":"Oprea-Lager","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"4","key":"10.1016\/j.fjurol.2024.102710_bib1240","doi-asserted-by":"crossref","first-page":"579","DOI":"10.2967\/jnumed.122.264743","article-title":"Phase III study of (18)F-PSMA-1007 versus (18)F-Fluorocholine PET\/CT for localization of prostate cancer biochemical recurrence: a prospective, randomized, crossover multicenter study","volume":"64","author":"Olivier","year":"2023","journal-title":"J Nucl Med"},{"issue":"6","key":"10.1016\/j.fjurol.2024.102710_bib1245","doi-asserted-by":"crossref","first-page":"852","DOI":"10.2214\/AJR.22.28665","article-title":"PI-RR: the prostate imaging for recurrence reporting system for MRI assessment of local prostate cancer recurrence after radiation therapy or radical prostatectomy\u00a0\u2013\u00a0a review","volume":"220","author":"Abreu-Gomez","year":"2023","journal-title":"AJR Am J Roentgenol"},{"issue":"4","key":"10.1016\/j.fjurol.2024.102710_bib1250","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.euo.2023.02.013","article-title":"Prostatectomy bed image-guided dose-escalated salvage radiotherapy (SPIDER): an international multicenter retrospective study","volume":"6","author":"Benziane-Ouaritini","year":"2023","journal-title":"Eur Urol Oncol"},{"issue":"6","key":"10.1016\/j.fjurol.2024.102710_bib1255","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S1470-2045(16)00111-X","article-title":"Salvage radiotherapy with or without short-term hormone therapy for rising prostate-specific antigen concentration after radical prostatectomy (GETUG-AFU 16): a randomised, multicentre, open-label phase 3 trial","volume":"17","author":"Carrie","year":"2016","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.fjurol.2024.102710_bib1260","doi-asserted-by":"crossref","first-page":"1740","DOI":"10.1016\/S1470-2045(19)30486-3","article-title":"Short-term androgen deprivation therapy combined with radiotherapy as salvage treatment after radical prostatectomy for prostate cancer (GETUG-AFU 16): a 112-month follow-up of a phase 3, randomised trial","volume":"20","author":"Carrie","year":"2019","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.fjurol.2024.102710_bib1265","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMoa1607529","article-title":"Radiation with or without antiandrogen therapy in recurrent prostate cancer","volume":"376","author":"Shipley","year":"2017","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.fjurol.2024.102710_bib1270","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1001\/jamaoncol.2020.0109","article-title":"Association of presalvage radiotherapy PSA levels after prostatectomy with outcomes of long-term antiandrogen therapy in men with prostate cancer","volume":"6","author":"Dess","year":"2020","journal-title":"JAMA Oncol"},{"issue":"10442","key":"10.1016\/j.fjurol.2024.102710_bib1275","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1016\/S0140-6736(24)00548-8","article-title":"Adding 6 months of androgen deprivation therapy to postoperative radiotherapy for prostate cancer: a comparison of short-course versus no androgen deprivation therapy in the RADICALS-HD randomised controlled trial","volume":"403","author":"Parker","year":"2024","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.fjurol.2024.102710_bib1280","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.eururo.2017.06.027","article-title":"A systematic review and framework for the use of hormone therapy with salvage radiation therapy for recurrent prostate cancer","volume":"73","author":"Spratt","year":"2018","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.fjurol.2024.102710_bib1285","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1016\/j.eururo.2012.01.022","article-title":"Cancer control and functional outcomes of salvage radical prostatectomy for radiation-recurrent prostate cancer: a systematic review of the literature","volume":"61","author":"Chade","year":"2012","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.fjurol.2024.102710_bib1290","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/j.eururo.2020.05.003","article-title":"Techniques and outcomes of salvage robot-assisted radical prostatectomy (sRARP)","volume":"78","author":"De Groote","year":"2020","journal-title":"Eur Urol"},{"issue":"22.","key":"10.1016\/j.fjurol.2024.102710_bib1295","doi-asserted-by":"crossref","first-page":"5485","DOI":"10.3390\/cancers15225485","article-title":"Salvage radical prostatectomy for recurrent prostate cancer: a systematic review (French ccAFU)","volume":"15","author":"Saouli","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"6\u20137","key":"10.1016\/j.fjurol.2024.102710_bib1300","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.canrad.2017.07.026","article-title":"Management of local relapse after prostate cancer radiotherapy: surgery or radiotherapy?","volume":"21","author":"Hennequin","year":"2017","journal-title":"Cancer Radiother"},{"issue":"5","key":"10.1016\/j.fjurol.2024.102710_bib1305","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/j.ijrobp.2021.10.138","article-title":"Salvage low-dose-rate prostate brachytherapy: clinical outcomes of a phase 2 trial for local recurrence after external beam radiation therapy (NRG Oncology\/RTOG 0526)","volume":"112","author":"Crook","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"3","key":"10.1016\/j.fjurol.2024.102710_bib1310","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1016\/j.eururo.2020.11.010","article-title":"A systematic review and meta-analysis of local salvage therapies after radiotherapy for prostate cancer (MASTER)","volume":"80","author":"Valle","year":"2021","journal-title":"Eur Urol"},{"issue":"8","key":"10.1016\/j.fjurol.2024.102710_bib1315","doi-asserted-by":"crossref","first-page":"e026666","DOI":"10.1136\/bmjopen-2018-026666","article-title":"GETUG-AFU 31: a phase I\/II multicentre study evaluating the safety and efficacy of salvage stereotactic radiation in patients with intraprostatic tumour recurrence after external radiation therapy-study protocol","volume":"9","author":"Pasquier","year":"2019","journal-title":"BMJ Open"},{"issue":"2","key":"10.1016\/j.fjurol.2024.102710_bib1320","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.radonc.2012.09.014","article-title":"Locally recurrent prostate cancer after initial radiation therapy: early salvage high-intensity focused ultrasound improves oncologic outcomes","volume":"105","author":"Crouzet","year":"2012","journal-title":"Radiother Oncol"},{"issue":"9\u201310","key":"10.1016\/j.fjurol.2024.102710_bib1325","doi-asserted-by":"crossref","first-page":"325","DOI":"10.5489\/cuaj.3113","article-title":"Comparative morbidity of ablative energy-based salvage treatments for radio-recurrent prostate cancer","volume":"9","author":"Siddiqui","year":"2015","journal-title":"Can Urol Assoc J"},{"issue":"6","key":"10.1016\/j.fjurol.2024.102710_bib1330","doi-asserted-by":"crossref","first-page":"1204","DOI":"10.1016\/j.eururo.2012.02.051","article-title":"Salvage cryoablation for locally recurrent prostate cancer following primary radiotherapy","volume":"61","author":"Mouraviev","year":"2012","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.fjurol.2024.102710_bib1335","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.eururo.2010.12.012","article-title":"Disease-free survival following salvage cryotherapy for biopsy-proven radio-recurrent prostate cancer","volume":"60","author":"Williams","year":"2011","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.fjurol.2024.102710_bib1340","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1016\/S1470-2045(16)00107-8","article-title":"Timing of androgen-deprivation therapy in patients with prostate cancer with a rising PSA (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial","volume":"17","author":"Duchesne","year":"2016","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.fjurol.2024.102710_bib1345","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1016\/j.eururo.2015.11.023","article-title":"Role of hormonal treatment in prostate cancer patients with nonmetastatic disease recurrence after local curative treatment: a systematic review","volume":"69","author":"van den Bergh","year":"2016","journal-title":"Eur Urol"},{"issue":"10","key":"10.1016\/j.fjurol.2024.102710_bib1350","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1056\/NEJMoa1201546","article-title":"Intermittent androgen suppression for rising PSA level after radiotherapy","volume":"367","author":"Crook","year":"2012","journal-title":"N Engl J Med"},{"issue":"16","key":"10.1016\/j.fjurol.2024.102710_bib1355","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1056\/NEJMoa2303974","article-title":"Improved outcomes with enzalutamide in biochemically recurrent prostate cancer","volume":"389","author":"Freedland","year":"2023","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.fjurol.2024.102710_bib1360","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.eururo.2023.06.013","article-title":"Primary whole-gland ablation for the treatment of clinically localized prostate cancer: a focal therapy society best practice statement","volume":"84","author":"Deivasigamani","year":"2023","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.fjurol.2024.102710_bib1365","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1016\/j.eururo.2020.05.018","article-title":"Standardized nomenclature and surveillance methodologies after focal therapy and partial gland ablation for localized prostate cancer: an international multidisciplinary consensus","volume":"78","author":"Lebastchi","year":"2020","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.fjurol.2024.102710_bib1370","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.eururo.2014.01.001","article-title":"Focal therapy in prostate cancer: international multidisciplinary consensus on trial design","volume":"65","author":"van den Bos","year":"2014","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.fjurol.2024.102710_bib1375","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1007\/s00345-016-1932-1","article-title":"Utilization of multiparametric prostate magnetic resonance imaging in clinical practice and focal therapy: report from a Delphi consensus project","volume":"35","author":"Scheltema","year":"2017","journal-title":"World J Urol"},{"key":"10.1016\/j.fjurol.2024.102710_bib1380","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.euros.2024.02.012","article-title":"Evaluating diagnostic accuracy and inter-reader agreement of the prostate imaging after focal ablation scoring system","volume":"62","author":"Gelikman","year":"2024","journal-title":"Eur Urol Open Sci"},{"key":"10.1016\/j.fjurol.2024.102710_bib1385","doi-asserted-by":"crossref","first-page":"104149","DOI":"10.1016\/j.critrevonc.2023.104149","article-title":"Salvage radiotherapy after initial cryotherapy for localized prostate cancer: a systematic review of the literature","volume":"192","author":"Roge","year":"2023","journal-title":"Crit Rev Oncol Hematol"},{"issue":"4","key":"10.1016\/j.fjurol.2024.102710_bib1390","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/j.juro.2015.04.103","article-title":"Management of node only recurrence after primary local treatment for prostate cancer: a systematic review of the literature","volume":"194","author":"Ploussard","year":"2015","journal-title":"J Urol"},{"issue":"4","key":"10.1016\/j.fjurol.2024.102710_bib1395","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1016\/j.eururo.2018.10.041","article-title":"Salvage lymph node dissection for nodal recurrent prostate cancer: a systematic review","volume":"76","author":"Ploussard","year":"2019","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.fjurol.2024.102710_bib1400","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1016\/j.eururo.2020.06.043","article-title":"Long-term outcomes of salvage lymph node dissection for nodal recurrence of prostate cancer after radical prostatectomy: not as good as previously thought","volume":"78","author":"Bravi","year":"2020","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.fjurol.2024.102710_bib1405","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.eururo.2021.06.010","article-title":"OLIGOPELVIS GETUG P07, a multicenter phase II trial of combined high-dose salvage radiotherapy and hormone therapy in oligorecurrent pelvic node relapses in prostate cancer","volume":"80","author":"Supiot","year":"2021","journal-title":"Eur Urol"},{"issue":"24","key":"10.1016\/j.fjurol.2024.102710_bib1410","first-page":"022131","article-title":"Long-term outcomes and patterns of relapse following high-dose elective salvage radiotherapy and hormone therapy in oligorecurrent pelvic nodes in prostate cancer: OLIGOPELVIS (GETUG-P07)","volume":"14","author":"Vaugier","year":"2024","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.fjurol.2024.102710_bib1415","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1007\/s00259-018-4159-0","article-title":"Salvage extended field or involved field nodal irradiation in (18)F-fluorocholine PET\/CT oligorecurrent nodal failures from prostate cancer","volume":"46","author":"Lepinoy","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"2","key":"10.1016\/j.fjurol.2024.102710_bib1420","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.eururo.2014.02.011","article-title":"Long-term outcomes of salvage lymph node dissection for clinically recurrent prostate cancer: results of a single-institution series with a minimum follow-up of 5 years","volume":"67","author":"Suardi","year":"2015","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.fjurol.2024.102710_bib1425","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1016\/j.eururo.2018.09.009","article-title":"Identifying the optimal candidate for salvage lymph node dissection for nodal recurrence of prostate cancer: results from a large, multi-institutional analysis","volume":"75","author":"Fossati","year":"2019","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.fjurol.2024.102710_bib1430","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1007\/s00066-014-0763-5","article-title":"Adjuvant radiotherapy after salvage lymph node dissection because of nodal relapse of prostate cancer versus salvage lymph node dissection only","volume":"191","author":"Rischke","year":"2015","journal-title":"Strahlenther Onkol"},{"issue":"6","key":"10.1016\/j.fjurol.2024.102710_bib1435","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1016\/S0090-4295(00)00793-7","article-title":"Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making","volume":"56","author":"Oefelein","year":"2000","journal-title":"Urology"},{"issue":"3","key":"10.1016\/j.fjurol.2024.102710_bib1440","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.eururo.2015.04.023","article-title":"Survivorship and improving quality of life in men with prostate cancer","volume":"68","author":"Bourke","year":"2015","journal-title":"Eur Urol"},{"issue":"4","key":"10.1016\/j.fjurol.2024.102710_bib1445","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1016\/j.eururo.2015.10.047","article-title":"Exercise for men with prostate cancer: a systematic review and meta-analysis","volume":"69","author":"Bourke","year":"2016","journal-title":"Eur Urol"},{"issue":"9","key":"10.1016\/j.fjurol.2024.102710_bib1450","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1200\/JCO.2014.60.2557","article-title":"Prostate cancer survivorship care guideline: American Society of Clinical Oncology Clinical Practice Guideline endorsement","volume":"33","author":"Resnick","year":"2015","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.fjurol.2024.102710_bib1455","doi-asserted-by":"crossref","first-page":"325","DOI":"10.1002\/jbmr.1771","article-title":"Vertebral fractures and trabecular microstructure in men with prostate cancer on androgen deprivation therapy","volume":"28","author":"Greenspan","year":"2013","journal-title":"J Bone Miner Res"},{"issue":"3","key":"10.1016\/j.fjurol.2024.102710_bib1460","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1016\/j.urology.2006.11.002","article-title":"Prevalence of osteoporosis during long-term androgen deprivation therapy in patients with prostate cancer","volume":"69","author":"Morote","year":"2007","journal-title":"Urology"},{"issue":"1","key":"10.1016\/j.fjurol.2024.102710_bib1465","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.jbspin.2018.09.017","article-title":"French recommendations for osteoporosis prevention and treatment in patients with prostate cancer treated by androgen deprivation","volume":"86","author":"Briot","year":"2019","journal-title":"Joint Bone Spine"},{"issue":"2","key":"10.1016\/j.fjurol.2024.102710_bib1470","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S1470-2045(09)70338-9","article-title":"Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: a double-blind, randomised trial","volume":"11","author":"Irani","year":"2010","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.fjurol.2024.102710_bib1475","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/j.1464-410X.2006.06176.x","article-title":"Optimizing outcomes and quality of life in the hormonal treatment of prostate cancer","volume":"98","author":"Mottet","year":"2006","journal-title":"BJU Int"},{"issue":"4","key":"10.1016\/j.fjurol.2024.102710_bib1480","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1038\/s41391-021-00406-4","article-title":"Exercise medicine in men with prostate cancer: breaking barriers to increase participation","volume":"24","author":"Galvao","year":"2021","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"3","key":"10.1016\/j.fjurol.2024.102710_bib1485","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1017\/S1041610296002724","article-title":"Utilization of the Draw a Person Test in the elderly","volume":"8","author":"Clement","year":"1996","journal-title":"Int Psychogeriatr"},{"issue":"10","key":"10.1016\/j.fjurol.2024.102710_bib1490","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1046\/j.1532-5415.2003.51465.x","article-title":"The Mini-Cog as a screen for dementia: validation in a population-based sample","volume":"51","author":"Borson","year":"2003","journal-title":"J Am Geriatr Soc"},{"issue":"3","key":"10.1016\/j.fjurol.2024.102710_bib1495","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1002\/cncr.21642","article-title":"Hyperglycemia and insulin resistance in men with prostate carcinoma who receive androgen-deprivation therapy","volume":"106","author":"Basaria","year":"2006","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.fjurol.2024.102710_bib1500","doi-asserted-by":"crossref","first-page":"3313","DOI":"10.1210\/jc.2003-031069","article-title":"The effect of testosterone replacement on endogenous inflammatory cytokines and lipid profiles in hypogonadal men","volume":"89","author":"Malkin","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.fjurol.2024.102710_bib1505","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1161\/CIRCULATIONAHA.115.012519","article-title":"Cardiovascular effects of androgen deprivation therapy for the treatment of prostate cancer: ABCDE steps to reduce cardiovascular disease in patients with prostate cancer","volume":"133","author":"Bhatia","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.fjurol.2024.102710_bib1510","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.ejca.2021.08.032","article-title":"A phase 2 randomized clinical trial of abiraterone plus ADT, apalutamide, or abiraterone and apalutamide in patients with advanced prostate cancer with non-castrate testosterone levels (LACOG 0415)","volume":"158","author":"Maluf","year":"2021","journal-title":"Eur J Cancer"},{"issue":"4","key":"10.1016\/j.fjurol.2024.102710_bib1515","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1038\/s41391-023-00682-2","article-title":"LHRH sparing therapy in patients with chemotherapy-naive, mCRPC treated with abiraterone acetate plus prednisone: results of the randomized phase II SPARE trial","volume":"26","author":"Ohlmann","year":"2022","journal-title":"Prostate Cancer Prostatic Dis"},{"issue":"9","key":"10.1016\/j.fjurol.2024.102710_bib1520","doi-asserted-by":"crossref","first-page":"1052","DOI":"10.1038\/s41416-018-0123-9","article-title":"Phase II pilot study of the prednisone to dexamethasone switch in metastatic castration-resistant prostate cancer (mCRPC) patients with limited progression on abiraterone plus prednisone (SWITCH study)","volume":"119","author":"Romero-Laorden","year":"2018","journal-title":"Br J Cancer"},{"issue":"24","key":"10.1016\/j.fjurol.2024.102710_bib1525","first-page":"00057","article-title":"A prospective randomised trial to determine the effect of a reduced versus standard dose of enzalutamide on side effects in frail patients with prostate cancer","volume":"13","author":"Boerrigter","year":"2024","journal-title":"Eur Urol Oncol"},{"issue":"14","key":"10.1016\/j.fjurol.2024.102710_bib1530","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.2217\/fon-2020-1104","article-title":"Apalutamide, darolutamide and enzalutamide in nonmetastatic castration-resistant prostate cancer: a meta-analysis","volume":"17","author":"Roumiguie","year":"2021","journal-title":"Future Oncol"},{"issue":"10024","key":"10.1016\/j.fjurol.2024.102710_bib1535","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.1016\/S0140-6736(15)01037-5","article-title":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial","volume":"387","author":"James","year":"2016","journal-title":"Lancet"},{"issue":"19","key":"10.1016\/j.fjurol.2024.102710_bib1540","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","article-title":"A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma","volume":"94","author":"Saad","year":"2002","journal-title":"J Natl Cancer Inst"},{"issue":"9768","key":"10.1016\/j.fjurol.2024.102710_bib1545","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(10)62344-6","article-title":"Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study","volume":"377","author":"Fizazi","year":"2011","journal-title":"Lancet"},{"issue":"2","key":"10.1016\/j.fjurol.2024.102710_bib1550","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1093\/annonc\/mdu519","article-title":"Denosumab for the prevention of skeletal complications in metastatic castration-resistant prostate cancer: comparison of skeletal-related events and symptomatic skeletal events","volume":"26","author":"Smith","year":"2015","journal-title":"Ann Oncol"},{"issue":"9810","key":"10.1016\/j.fjurol.2024.102710_bib1555","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(11)61226-9","article-title":"Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial","volume":"379","author":"Smith","year":"2012","journal-title":"Lancet"},{"issue":"3","key":"10.1016\/j.fjurol.2024.102710_bib1560","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1016\/S1470-2045(18)30860-X","article-title":"Addition of radium-223 to abiraterone acetate and prednisone or prednisolone in patients with castration-resistant prostate cancer and bone metastases (ERA 223): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"20","author":"Smith","year":"2019","journal-title":"Lancet Oncol"},{"issue":"12","key":"10.1016\/j.fjurol.2024.102710_bib1565","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1016\/S1470-2045(14)70474-7","volume":"15","author":"Hoskin","year":"2014","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.fjurol.2024.102710_bib1570","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1056\/NEJMoa1213755","article-title":"Alpha emitter radium-223 and survival in metastatic prostate cancer","volume":"369","author":"Parker","year":"2013","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.fjurol.2024.102710_bib1575","doi-asserted-by":"crossref","first-page":"738","DOI":"10.1016\/S1470-2045(14)70183-4","article-title":"Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: results from a phase 3, double-blind, randomised trial","volume":"15","author":"Sartor","year":"2014","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.fjurol.2024.102710_bib1580","doi-asserted-by":"crossref","first-page":"914","DOI":"10.2967\/jnumed.114.147413","article-title":"Preclinical evaluation of a tailor-made DOTA-conjugated PSMA inhibitor with optimized linker moiety for imaging and endoradiotherapy of prostate cancer","volume":"56","author":"Benesova","year":"2015","journal-title":"J Nucl Med"},{"issue":"1","key":"10.1016\/j.fjurol.2024.102710_bib1585","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1053\/j.semnuclmed.2019.07.003","article-title":"PSMA-based theranostics: a step-by-step practical approach to diagnosis and therapy for mCRPC patients","volume":"50","author":"Ahmadzadehfar","year":"2020","journal-title":"Semin Nucl Med"},{"issue":"12","key":"10.1016\/j.fjurol.2024.102710_bib1590","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1007\/s00259-019-04485-3","article-title":"EANM procedure guidelines for radionuclide therapy with (177)Lu-labelled PSMA-ligands ((177)Lu-PSMA-RLT)","volume":"46","author":"Kratochwil","year":"2019","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"12","key":"10.1016\/j.fjurol.2024.102710_bib1595","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177-PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.fjurol.2024.102710_bib1600","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/S1470-2045(18)30198-0","article-title":"[(177)Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study","volume":"19","author":"Hofman","year":"2018","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.fjurol.2024.102710_bib1605","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2967\/jnumed.116.183194","article-title":"German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients","volume":"58","author":"Rahbar","year":"2017","journal-title":"J Nucl Med"},{"issue":"5","key":"10.1016\/j.fjurol.2024.102710_bib1610","doi-asserted-by":"crossref","first-page":"795","DOI":"10.2967\/jnumed.117.203539","article-title":"Targeted alpha-therapy of metastatic castration-resistant prostate cancer with (225)Ac-PSMA-617: swimmer-plot analysis suggests efficacy regarding duration of tumor control","volume":"59","author":"Kratochwil","year":"2018","journal-title":"J Nucl Med"},{"issue":"7","key":"10.1016\/j.fjurol.2024.102710_bib1615","doi-asserted-by":"crossref","first-page":"955","DOI":"10.2967\/jnumed.118.216820","article-title":"Clinical outcomes of (177)Lu-PSMA Radioligand therapy in earlier and later phases of metastatic castration-resistant prostate cancer grouped by previous taxane chemotherapy","volume":"60","author":"Barber","year":"2019","journal-title":"J Nucl Med"},{"issue":"24","key":"10.1016\/j.fjurol.2024.102710_bib1620","doi-asserted-by":"crossref","first-page":"2345","DOI":"10.1056\/NEJMoa2022485","article-title":"Survival with olaparib in metastatic castration-resistant prostate cancer","volume":"383","author":"Hussain","year":"2020","journal-title":"N Engl J Med"},{"issue":"6.","key":"10.1016\/j.fjurol.2024.102710_bib1625","doi-asserted-by":"crossref","first-page":"1734","DOI":"10.3390\/jcm11061734","article-title":"PARP inhibitors as monotherapy in daily practice for advanced prostate cancers","volume":"11","author":"Teyssonneau","year":"2022","journal-title":"J Clin Med"},{"issue":"8","key":"10.1016\/j.fjurol.2024.102710_bib1630","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1056\/NEJMoa2214676","article-title":"Rucaparib or physician's choice in metastatic prostate cancer","volume":"388","author":"Fizazi","year":"2023","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.fjurol.2024.102710_bib1635","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1016\/S1470-2045(18)30365-6","article-title":"Olaparib combined with abiraterone in patients with metastatic castration-resistant prostate cancer: a randomised, double-blind, placebo-controlled, phase 2 trial","volume":"19","author":"Clarke","year":"2018","journal-title":"Lancet Oncol"},{"issue":"10","key":"10.1016\/j.fjurol.2024.102710_bib1640","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/S1470-2045(23)00382-0","article-title":"Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial","volume":"24","author":"Saad","year":"2023","journal-title":"Lancet Oncol"},{"issue":"9","key":"10.1016\/j.fjurol.2024.102710_bib1645","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.annonc.2023.06.009","article-title":"Niraparib plus abiraterone acetate with prednisone in patients with metastatic castration-resistant prostate cancer and homologous recombination repair gene alterations: second interim analysis of the randomized phase III MAGNITUDE trial","volume":"34","author":"Chi","year":"2023","journal-title":"Ann Oncol"},{"issue":"10398","key":"10.1016\/j.fjurol.2024.102710_bib1650","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/S0140-6736(23)01055-3","article-title":"Talazoparib plus enzalutamide in men with first-line metastatic castration-resistant prostate cancer (TALAPRO-2): a randomised, placebo-controlled, phase 3 trial","volume":"402","author":"Agarwal","year":"2023","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.fjurol.2024.102710_bib1655","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1038\/s41591-023-02704-x","article-title":"First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial","volume":"30","author":"Fizazi","year":"2024","journal-title":"Nat Med"},{"issue":"3","key":"10.1016\/j.fjurol.2024.102710_bib1660","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.purol.2021.12.007","article-title":"[DNA repair gene alterations testing in prostate cancer: a practical update by the Prostate Cancer Committee of the French Association of Urology]","volume":"32","author":"Ploussard","year":"2022","journal-title":"Prog Urol"},{"issue":"2","key":"10.1016\/j.fjurol.2024.102710_bib1665","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.cell.2015.06.053","article-title":"Integrative clinical genomics of advanced prostate cancer","volume":"162","author":"Robinson","year":"2015","journal-title":"Cell"},{"issue":"5","key":"10.1016\/j.fjurol.2024.102710_bib1670","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/j.ccr.2011.04.008","article-title":"Reciprocal feedback regulation of PI3K and androgen receptor signaling in PTEN-deficient prostate cancer","volume":"19","author":"Carver","year":"2011","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.fjurol.2024.102710_bib1675","doi-asserted-by":"crossref","first-page":"928","DOI":"10.1158\/1078-0432.CCR-18-0981","article-title":"Randomized phase II study evaluating Akt blockade with ipatasertib, in combination with abiraterone, in patients with metastatic prostate cancer with and without PTEN loss","volume":"25","author":"de Bono","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"10295","key":"10.1016\/j.fjurol.2024.102710_bib1680","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/S0140-6736(21)00580-8","article-title":"Ipatasertib plus abiraterone and prednisolone in metastatic castration-resistant prostate cancer (IPATential150): a multicentre, randomised, double-blind, phase 3 trial","volume":"398","author":"Sweeney","year":"2021","journal-title":"Lancet"},{"issue":"1.","key":"10.1016\/j.fjurol.2024.102710_bib1685","doi-asserted-by":"crossref","first-page":"160","DOI":"10.3390\/jcm11010160","article-title":"Overview of the development and use of Akt inhibitors in prostate cancer","volume":"11","author":"Gasmi","year":"2021","journal-title":"J Clin Med"},{"issue":"1","key":"10.1016\/j.fjurol.2024.102710_bib1690","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1200\/JCO.2016.69.1584","article-title":"Randomized, double-blind, phase III trial of ipilimumab versus placebo in asymptomatic or minimally symptomatic patients with metastatic chemotherapy-naive castration-resistant prostate cancer","volume":"35","author":"Beer","year":"2017","journal-title":"J Clin Oncol"},{"issue":"7","key":"10.1016\/j.fjurol.2024.102710_bib1695","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/S1470-2045(14)70189-5","article-title":"Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial","volume":"15","author":"Kwon","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.fjurol.2024.102710_bib1700","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1200\/PO.19.00399","article-title":"CDK12-altered prostate cancer: clinical features and therapeutic outcomes to standard systemic therapies, poly (ADP-Ribose) polymerase inhibitors, and PD-1 inhibitors","volume":"4","author":"Antonarakis","year":"2020","journal-title":"JCO Precis Oncol"},{"issue":"1","key":"10.1016\/j.fjurol.2024.102710_bib1705","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41591-021-01600-6","article-title":"Atezolizumab with enzalutamide versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized phase 3 trial","volume":"28","author":"Powles","year":"2022","journal-title":"Nat Med"},{"issue":"4","key":"10.1016\/j.fjurol.2024.102710_bib1710","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.ccell.2020.08.007","article-title":"Nivolumab plus ipilimumab for metastatic castration-resistant prostate cancer: preliminary analysis of patients in the CheckMate 650 Trial","volume":"38","author":"Sharma","year":"2020","journal-title":"Cancer Cell"},{"issue":"12","key":"10.1016\/j.fjurol.2024.102710_bib1715","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1002\/pros.23645","article-title":"Time of metastatic disease presentation and volume of disease are prognostic for metastatic hormone sensitive prostate cancer (mHSPC)","volume":"78","author":"Francini","year":"2018","journal-title":"Prostate"},{"issue":"5","key":"10.1016\/j.fjurol.2024.102710_bib1720","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1016\/S1470-2045(19)30082-8","article-title":"Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial","volume":"20","author":"Fizazi","year":"2019","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.fjurol.2024.102710_bib1725","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1056\/NEJMoa1503747","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer","volume":"373","author":"Sweeney","year":"2015","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.fjurol.2024.102710_bib1730","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1016\/j.urolonc.2017.12.009","article-title":"Metastatic burden in newly diagnosed hormone-naive metastatic prostate cancer: comparing definitions of CHAARTED and LATITUDE trial","volume":"36","author":"Buelens","year":"2018","journal-title":"Urol Oncol"},{"issue":"3","key":"10.1016\/j.fjurol.2024.102710_bib1735","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1002\/cncr.31860","article-title":"Oligometastatic prostate cancer: reality or figment of imagination?","volume":"125","author":"Foster","year":"2019","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.fjurol.2024.102710_bib1740","doi-asserted-by":"crossref","first-page":"e18","DOI":"10.1016\/S1470-2045(19)30718-1","article-title":"Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation","volume":"21","author":"Guckenberger","year":"2020","journal-title":"Lancet Oncol"},{"issue":"11","key":"10.1016\/j.fjurol.2024.102710_bib1745","doi-asserted-by":"crossref","first-page":"8491","DOI":"10.18632\/oncotarget.3455","article-title":"The biology and treatment of oligometastatic cancer","volume":"6","author":"Reyes","year":"2015","journal-title":"Oncotarget"},{"issue":"16","key":"10.1016\/j.fjurol.2024.102710_bib1750","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.1161\/CIRCULATIONAHA.121.056810","article-title":"Cardiovascular safety of degarelix versus leuprolide in patients with prostate cancer: the primary results of the PRONOUNCE randomized trial","volume":"144","author":"Lopes","year":"2021","journal-title":"Circulation"},{"issue":"23","key":"10.1016\/j.fjurol.2024.102710_bib1755","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1056\/NEJMoa2004325","article-title":"Oral relugolix for androgen-deprivation therapy in advanced prostate cancer","volume":"382","author":"Shore","year":"2020","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.fjurol.2024.102710_bib1760","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.eururo.2013.10.032","article-title":"Cardiovascular morbidity associated with gonadotropin releasing hormone agonists and an antagonist","volume":"65","author":"Albertsen","year":"2014","journal-title":"Eur Urol"},{"issue":"6","key":"10.1016\/j.fjurol.2024.102710_bib1765","first-page":"CD009266","article-title":"Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer","author":"Kunath","year":"2014","journal-title":"Cochrane Database Syst Rev"},{"issue":"9214","key":"10.1016\/j.fjurol.2024.102710_bib1770","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1016\/S0140-6736(00)02163-2","article-title":"Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists\u2019 Collaborative Group","volume":"355","year":"2000","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.fjurol.2024.102710_bib1775","first-page":"CD003506","article-title":"Early versus deferred androgen suppression in the treatment of advanced prostatic cancer","author":"Nair","year":"2002","journal-title":"Cochrane Database Syst Rev"},{"issue":"14","key":"10.1016\/j.fjurol.2024.102710_bib1780","doi-asserted-by":"crossref","first-page":"1314","DOI":"10.1056\/NEJMoa1212299","article-title":"Intermittent versus continuous androgen deprivation in prostate cancer","volume":"368","author":"Hussain","year":"2013","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.fjurol.2024.102710_bib1785","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1200\/JCO.2015.62.8065","article-title":"Evaluating intermittent Androgen-deprivation therapy phase III clinical trials: the devil is in the details","volume":"34","author":"Hussain","year":"2016","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.1016\/j.fjurol.2024.102710_bib1790","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1001\/jamaoncol.2015.2895","article-title":"Intermittent vs. continuous androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis","volume":"1","author":"Magnan","year":"2015","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.fjurol.2024.102710_bib1795","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.eururo.2012.07.040","article-title":"Advanced prostate cancer treated with intermittent or continuous androgen deprivation in the randomised FinnProstate Study VII: quality of life and adverse effects","volume":"63","author":"Salonen","year":"2013","journal-title":"Eur Urol"},{"issue":"12","key":"10.1016\/j.fjurol.2024.102710_bib1800","doi-asserted-by":"crossref","first-page":"1992","DOI":"10.1093\/annonc\/mdz396","article-title":"Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial","volume":"30","author":"Clarke","year":"2019","journal-title":"Ann Oncol"},{"issue":"2","key":"10.1016\/j.fjurol.2024.102710_bib1805","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.eururo.2015.11.005","article-title":"Androgen Deprivation therapy (ADT) plus docetaxel versus ADT alone in metastatic non-castrate prostate cancer: impact of metastatic burden and long-term survival analysis of the randomized phase 3 GETUG-AFU15 trial","volume":"70","author":"Gravis","year":"2016","journal-title":"Eur Urol"},{"issue":"100324","key":"10.1016\/j.fjurol.2024.102710_bib1810","first-page":"1163","article-title":"Addition of docetaxel, zoledronic acid, or both to first-line long-term hormone therapy in prostate cancer (STAMPEDE): survival results from an adaptive, multiarm, multistage, platform randomised controlled trial","volume":"19","author":"James","year":"2015","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.fjurol.2024.102710_bib1815","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1200\/JCO.2017.75.3657","article-title":"Chemohormonal therapy in metastatic hormone-sensitive prostate cancer: long-term survival analysis of the randomized phase III E3805 CHAARTED trial","volume":"36","author":"Kyriakopoulos","year":"2018","journal-title":"J Clin Oncol"},{"issue":"2","key":"10.1016\/j.fjurol.2024.102710_bib1820","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S1470-2045(15)00489-1","article-title":"Addition of docetaxel or bisphosphonates to standard of care in men with localised or metastatic, hormone-sensitive prostate cancer: a systematic review and meta-analyses of aggregate data","volume":"17","author":"Vale","year":"2016","journal-title":"Lancet Oncol"},{"issue":"7","key":"10.1016\/j.fjurol.2024.102710_bib1825","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1016\/S1470-2045(23)00230-9","article-title":"Which patients with metastatic hormone-sensitive prostate cancer benefit from docetaxel: a systematic review and meta-analysis of individual participant data from randomised trials","volume":"24","author":"Vale","year":"2023","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.fjurol.2024.102710_bib1830","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1056\/NEJMoa1702900","article-title":"Abiraterone for prostate cancer not previously treated with hormone therapy","volume":"377","author":"James","year":"2017","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.fjurol.2024.102710_bib1835","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1056\/NEJMoa1903835","article-title":"Enzalutamide with standard first-line therapy in metastatic prostate cancer","volume":"381","author":"Davis","year":"2019","journal-title":"N Engl J Med"},{"issue":"32","key":"10.1016\/j.fjurol.2024.102710_bib1840","doi-asserted-by":"crossref","first-page":"2974","DOI":"10.1200\/JCO.19.00799","article-title":"ARCHES: a randomized, phase III study of androgen deprivation therapy with enzalutamide or placebo in men with metastatic hormone-sensitive prostate cancer","volume":"37","author":"Armstrong","year":"2019","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.fjurol.2024.102710_bib1845","doi-asserted-by":"crossref","first-page":"1616","DOI":"10.1200\/JCO.22.00193","article-title":"Improved survival with enzalutamide in patients with metastatic hormone-sensitive prostate cancer","volume":"40","author":"Armstrong","year":"2022","journal-title":"J Clin Oncol"},{"issue":"4","key":"10.1016\/j.fjurol.2024.102710_bib1850","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.eururo.2020.03.019","article-title":"Effect of enzalutamide plus androgen deprivation therapy on health-related quality of life in patients with metastatic hormone-sensitive prostate cancer: an analysis of the ARCHES randomised, placebo-controlled, phase 3 study","volume":"78","author":"Stenzl","year":"2020","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.fjurol.2024.102710_bib1855","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1056\/NEJMoa1903307","article-title":"Apalutamide for metastatic, castration-sensitive prostate cancer","volume":"381","author":"Chi","year":"2019","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.fjurol.2024.102710_bib1860","doi-asserted-by":"crossref","first-page":"2294","DOI":"10.1200\/JCO.20.03488","article-title":"Apalutamide in patients with metastatic castration-sensitive prostate cancer: final survival analysis of the randomized, double-blind, phase III TITAN Study","volume":"39","author":"Chi","year":"2021","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.fjurol.2024.102710_bib1865","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1016\/S1470-2045(19)30620-5","article-title":"Health-related quality of life after apalutamide treatment in patients with metastatic castration-sensitive prostate cancer (TITAN): a randomised, placebo-controlled, phase 3 study","volume":"20","author":"Agarwal","year":"2019","journal-title":"Lancet Oncol"},{"issue":"10336","key":"10.1016\/j.fjurol.2024.102710_bib1870","doi-asserted-by":"crossref","first-page":"1695","DOI":"10.1016\/S0140-6736(22)00367-1","article-title":"Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2\u00a0\u00d7\u00a02 factorial design","volume":"399","author":"Fizazi","year":"2022","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.fjurol.2024.102710_bib1875","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1056\/NEJMoa2119115","article-title":"Darolutamide and survival in metastatic, hormone-sensitive prostate cancer","volume":"386","author":"Smith","year":"2022","journal-title":"N Engl J Med"},{"issue":"20","key":"10.1016\/j.fjurol.2024.102710_bib1880","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1200\/JCO.23.00041","article-title":"Darolutamide plus androgen-deprivation therapy and docetaxel in metastatic hormone-sensitive prostate cancer by disease volume and risk subgroups in the phase III ARASENS trial","volume":"41","author":"Hussain","year":"2023","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.fjurol.2024.102710_bib1885","doi-asserted-by":"crossref","first-page":"102441","DOI":"10.1016\/j.ctrv.2022.102441","article-title":"Chemotherapy and advanced androgen blockage, alone or combined, for metastatic hormone-sensitive prostate cancer a systematic review and meta-analysis","volume":"110","author":"Fallara","year":"2022","journal-title":"Cancer Treat Rev"},{"issue":"5","key":"10.1016\/j.fjurol.2024.102710_bib1890","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/j.euf.2023.03.024","article-title":"Triplet or Doublet therapy in metastatic hormone-sensitive prostate cancer: updated network meta-analysis stratified by disease volume","volume":"9","author":"Hoeh","year":"2023","journal-title":"Eur Urol Focus"},{"issue":"5","key":"10.1016\/j.fjurol.2024.102710_bib1895","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1001\/jamaoncol.2022.7762","article-title":"First-line systemic treatment options for metastatic castration-sensitive prostate cancer: a living systematic review and network meta-analysis","volume":"9","author":"Riaz","year":"2023","journal-title":"JAMA Oncol"},{"issue":"6","key":"10.1016\/j.fjurol.2024.102710_bib1900","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.eururo.2022.08.002","article-title":"Androgen receptor signaling inhibitors in addition to docetaxel with androgen deprivation therapy for metastatic hormone-sensitive prostate cancer: a systematic review and meta-analysis","volume":"82","author":"Yanagisawa","year":"2022","journal-title":"Eur Urol"},{"issue":"3","key":"10.1016\/j.fjurol.2024.102710_bib1905","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1016\/j.eururo.2018.09.008","volume":"75","author":"Boeve","year":"2019","journal-title":"Eur Urol"},{"issue":"10162","key":"10.1016\/j.fjurol.2024.102710_bib1910","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1016\/S0140-6736(18)32486-3","article-title":"Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial","volume":"392","author":"Parker","year":"2018","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.fjurol.2024.102710_bib1915","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1001\/jamaoncol.2020.7857","article-title":"Association of bone metastatic burden with survival benefit from prostate radiotherapy in patients with newly diagnosed metastatic prostate cancer: a secondary analysis of a randomized clinical trial","volume":"7","author":"Ali","year":"2021","journal-title":"JAMA Oncol"},{"issue":"1","key":"10.1016\/j.fjurol.2024.102710_bib1920","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.eururo.2019.02.003","article-title":"Prostate radiotherapy for metastatic hormone-sensitive prostate cancer: a STOPCAP systematic review and meta-analysis","volume":"76","author":"Burdett","year":"2019","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.fjurol.2024.102710_bib1925","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.eururo.2024.03.018","article-title":"Prostate radiotherapy in low-volume metastatic hormone-sensitive prostate cancer: a network meta-analysis","volume":"86","author":"Roy","year":"2024","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.fjurol.2024.102710_bib1930","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1200\/JCO.2017.75.4853","article-title":"Surveillance or metastasis-directed therapy for oligometastatic prostate cancer recurrence: a prospective, randomized, multicenter phase II trial","volume":"36","author":"Ost","year":"2018","journal-title":"J Clin Oncol"},{"issue":"10185","key":"10.1016\/j.fjurol.2024.102710_bib1935","doi-asserted-by":"crossref","first-page":"2051","DOI":"10.1016\/S0140-6736(18)32487-5","article-title":"Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): a randomised, phase 2, open-label trial","volume":"393","author":"Palma","year":"2019","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.fjurol.2024.102710_bib1940","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1016\/j.ijrobp.2022.05.004","article-title":"Stereotactic radiation for the comprehensive treatment of oligometastases (SABR-COMET): extended long-term outcomes","volume":"114","author":"Harrow","year":"2022","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"10.1016\/j.fjurol.2024.102710_bib1945","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1001\/jamaoncol.2020.0147","article-title":"Outcomes of observation vs. stereotactic ablative radiation for oligometastatic prostate cancer: the ORIOLE Phase 2 randomized clinical trial","volume":"6","author":"Phillips","year":"2020","journal-title":"JAMA Oncol"},{"issue":"6","key":"10.1016\/j.fjurol.2024.102710_bib1950","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1001\/jamaoncol.2023.0161","article-title":"Addition of metastasis-directed therapy to intermittent hormone therapy for oligometastatic prostate cancer: the EXTEND Phase 2 randomized clinical trial","volume":"9","author":"Tang","year":"2023","journal-title":"JAMA Oncol"},{"issue":"2","key":"10.1016\/j.fjurol.2024.102710_bib1955","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"issue":"24","key":"10.1016\/j.fjurol.2024.102710_bib1960","doi-asserted-by":"crossref","first-page":"7448","DOI":"10.1158\/1078-0432.CCR-19-1050","article-title":"Prostate-specific membrane antigen ligand positron emission tomography in men with nonmetastatic castration-resistant prostate cancer","volume":"25","author":"Fendler","year":"2019","journal-title":"Clin Cancer Res"},{"issue":"30","key":"10.1016\/j.fjurol.2024.102710_bib1965","doi-asserted-by":"crossref","first-page":"3800","DOI":"10.1200\/JCO.2012.44.6716","article-title":"Denosumab and bone metastasis-free survival in men with nonmetastatic castration-resistant prostate cancer: exploratory analyses by baseline prostate-specific antigen doubling time","volume":"31","author":"Smith","year":"2013","journal-title":"J Clin Oncol"},{"issue":"15","key":"10.1016\/j.fjurol.2024.102710_bib1970","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.1056\/NEJMoa1715546","article-title":"Apalutamide treatment and metastasis-free survival in prostate cancer","volume":"378","author":"Smith","year":"2018","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.fjurol.2024.102710_bib1975","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.eururo.2020.08.011","article-title":"Apalutamide and overall survival in prostate cancer","volume":"79","author":"Smith","year":"2021","journal-title":"Eur Urol"},{"issue":"26","key":"10.1016\/j.fjurol.2024.102710_bib1980","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1056\/NEJMoa1800536","article-title":"Enzalutamide in men with nonmetastatic, castration-resistant prostate cancer","volume":"378","author":"Hussain","year":"2018","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.fjurol.2024.102710_bib1985","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1056\/NEJMoa2003892","article-title":"Enzalutamide and survival in nonmetastatic, castration-resistant prostate cancer","volume":"382","author":"Sternberg","year":"2020","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.fjurol.2024.102710_bib1990","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1056\/NEJMoa1815671","article-title":"Darolutamide in nonmetastatic, castration-resistant prostate cancer","volume":"380","author":"Fizazi","year":"2019","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.fjurol.2024.102710_bib1995","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1016\/j.euf.2021.08.005","article-title":"Health-related quality of life at the SPARTAN final analysis of apalutamide for nonmetastatic castration-resistant prostate cancer patients receiving androgen deprivation therapy","volume":"8","author":"Oudard","year":"2021","journal-title":"Eur Urol Focus"},{"key":"10.1016\/j.fjurol.2024.102710_bib2000","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.ejca.2021.06.010","article-title":"Darolutamide and health-related quality of life in patients with non-metastatic castration-resistant prostate cancer: an analysis of the phase III ARAMIS trial","volume":"154","author":"Smith","year":"2021","journal-title":"Eur J Cancer"},{"issue":"23.","key":"10.1016\/j.fjurol.2024.102710_bib2005","doi-asserted-by":"crossref","first-page":"5872","DOI":"10.3390\/cancers13235872","article-title":"The impact of enzalutamide on the prostate cancer patient experience: a summary review of health-related quality of life across pivotal clinical trials","volume":"13","author":"Tombal","year":"2021","journal-title":"Cancers (Basel)"},{"issue":"15","key":"10.1016\/j.fjurol.2024.102710_bib2010","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1056\/NEJMoa040720","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","volume":"351","author":"Tannock","year":"2004","journal-title":"N Engl J Med"},{"issue":"13","key":"10.1016\/j.fjurol.2024.102710_bib2015","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1056\/NEJMoa1207506","article-title":"Increased survival with enzalutamide in prostate cancer after chemotherapy","volume":"367","author":"Scher","year":"2012","journal-title":"N Engl J Med"},{"issue":"14","key":"10.1016\/j.fjurol.2024.102710_bib2020","doi-asserted-by":"crossref","first-page":"4854","DOI":"10.1158\/1078-0432.CCR-11-0815","article-title":"Phase II study of abiraterone acetate in chemotherapy-naive metastatic castration-resistant prostate cancer displaying bone flare discordant with serologic response","volume":"17","author":"Ryan","year":"2011","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.fjurol.2024.102710_bib2025","doi-asserted-by":"crossref","first-page":"3986","DOI":"10.21037\/tau-20-1117","article-title":"ALP bouncing and LDH normalization in bone metastatic castration-resistant prostate cancer patients under therapy with Enzalutamide: an exploratory analysis","volume":"10","author":"Schlack","year":"2021","journal-title":"Transl Androl Urol"},{"issue":"9","key":"10.1016\/j.fjurol.2024.102710_bib2030","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1016\/j.ejca.2014.03.015","article-title":"Prostate-specific antigen flare induced by cabazitaxel-based chemotherapy in patients with metastatic castration-resistant prostate cancer","volume":"50","author":"Angelergues","year":"2014","journal-title":"Eur J Cancer"},{"issue":"10","key":"10.1016\/j.fjurol.2024.102710_bib2035","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1016\/S1470-2045(12)70379-0","article-title":"Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study","volume":"13","author":"Fizazi","year":"2012","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.fjurol.2024.102710_bib2040","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S1470-2045(14)71205-7","article-title":"Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study","volume":"16","author":"Ryan","year":"2015","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.fjurol.2024.102710_bib2045","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1056\/NEJMoa1405095","article-title":"Enzalutamide in metastatic prostate cancer before chemotherapy","volume":"371","author":"Beer","year":"2014","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.fjurol.2024.102710_bib2050","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/S1470-2045(15)00518-5","article-title":"Efficacy and safety of enzalutamide versus bicalutamide for patients with metastatic prostate cancer (TERRAIN): a randomised, double-blind, phase 2 study","volume":"17","author":"Shore","year":"2016","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.fjurol.2024.102710_bib2055","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1016\/j.eururo.2016.07.027","article-title":"Impact of enzalutamide compared with bicalutamide on quality of life in men with metastatic castration-resistant prostate cancer: additional analyses from the TERRAIN randomised clinical trial","volume":"71","author":"Heidenreich","year":"2017","journal-title":"Eur Urol"},{"issue":"18","key":"10.1016\/j.fjurol.2024.102710_bib2060","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1200\/JCO.2015.64.9285","article-title":"Enzalutamide versus bicalutamide in castration-resistant prostate cancer: the STRIVE TRIAL","volume":"34","author":"Penson","year":"2016","journal-title":"J Clin Oncol"},{"issue":"25","key":"10.1016\/j.fjurol.2024.102710_bib2065","doi-asserted-by":"crossref","first-page":"2639","DOI":"10.1200\/JCO.2018.77.9827","article-title":"Abiraterone alone or in combination with enzalutamide in metastatic castration-resistant prostate cancer with rising prostate-specific antigen during enzalutamide treatment","volume":"36","author":"Attard","year":"2018","journal-title":"J Clin Oncol"},{"issue":"11","key":"10.1016\/j.fjurol.2024.102710_bib2070","doi-asserted-by":"crossref","first-page":"1541","DOI":"10.1016\/S1470-2045(21)00402-2","article-title":"Apalutamide plus abiraterone acetate and prednisone versus placebo plus abiraterone and prednisone in metastatic, castration-resistant prostate cancer (ACIS): a randomised, placebo-controlled, double-blind, multinational, phase 3 study","volume":"22","author":"Saad","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.fjurol.2024.102710_bib2075","doi-asserted-by":"crossref","DOI":"10.1177\/17588359241242959","article-title":"PARP inhibitors in prostate cancers, is it time for combinations?","volume":"16","author":"Teyssonneau","year":"2024","journal-title":"Ther Adv Med Oncol"},{"issue":"2","key":"10.1016\/j.fjurol.2024.102710_bib2080","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S1470-2045(12)70537-5","article-title":"2-weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial","volume":"14","author":"Kellokumpu-Lehtinen","year":"2013","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.fjurol.2024.102710_bib2085","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1200\/JCO.2007.12.4008","article-title":"Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study","volume":"26","author":"Berthold","year":"2008","journal-title":"J Clin Oncol"},{"issue":"28","key":"10.1016\/j.fjurol.2024.102710_bib2090","doi-asserted-by":"crossref","first-page":"3189","DOI":"10.1200\/JCO.2016.72.1068","article-title":"Cabazitaxel versus docetaxel as first-line therapy for patients with metastatic castration-resistant prostate cancer: a randomized phase III Trial-FIRSTANA","volume":"35","author":"Oudard","year":"2017","journal-title":"J Clin Oncol"},{"issue":"28","key":"10.1016\/j.fjurol.2024.102710_bib2095","doi-asserted-by":"crossref","first-page":"3198","DOI":"10.1200\/JCO.2016.72.1076","article-title":"Phase III study comparing a reduced dose of cabazitaxel (20\u00a0mg\/m2) and the currently approved dose (25\u00a0mg\/m2) in postdocetaxel patients with metastatic castration-resistant prostate Cancer-PROSELICA","volume":"35","author":"Eisenberger","year":"2017","journal-title":"J Clin Oncol"},{"issue":"13","key":"10.1016\/j.fjurol.2024.102710_bib2100","doi-asserted-by":"crossref","first-page":"3621","DOI":"10.1158\/1078-0432.CCR-12-3791","article-title":"Platinum-based chemotherapy for variant castrate-resistant prostate cancer","volume":"19","author":"Aparicio","year":"2013","journal-title":"Clin Cancer Res"},{"issue":"14","key":"10.1016\/j.fjurol.2024.102710_bib2105","doi-asserted-by":"crossref","first-page":"1946","DOI":"10.1016\/j.ejca.2015.06.128","article-title":"Prior long response to androgen deprivation predicts response to next-generation androgen receptor axis targeted drugs in castration resistant prostate cancer","volume":"51","author":"Loriot","year":"2015","journal-title":"Eur J Cancer"},{"issue":"6","key":"10.1016\/j.fjurol.2024.102710_bib2110","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1111\/iju.13346","article-title":"Exploring the optimal sequence of abiraterone and enzalutamide in patients with chemotherapy-na\u00efve castration-resistant prostate cancer: the Kyoto-Baltimore collaboration","volume":"24","author":"Terada","year":"2017","journal-title":"Int J Urol"},{"issue":"2","key":"10.1016\/j.fjurol.2024.102710_bib2115","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1016\/j.clgc.2017.09.008","article-title":"Abiraterone followed by enzalutamide versus enzalutamide followed by abiraterone in chemotherapy-naive patients with metastatic castration-resistant prostate cancer","volume":"16","author":"Matsubara","year":"2018","journal-title":"Clin Genitourin Cancer"},{"issue":"12","key":"10.1016\/j.fjurol.2024.102710_bib2120","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.1016\/S1470-2045(19)30688-6","article-title":"Optimal sequencing of enzalutamide and abiraterone acetate plus prednisone in metastatic castration-resistant prostate cancer: a multicentre, randomised, open-label, phase 2, crossover trial","volume":"20","author":"Khalaf","year":"2019","journal-title":"Lancet Oncol"},{"issue":"8","key":"10.1016\/j.fjurol.2024.102710_bib2125","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.3390\/jcm8081251","article-title":"Comparison of radiographic progression-free survival and PSA response on sequential treatment using abiraterone and enzalutamide for newly diagnosed castration-resistant prostate cancer: a propensity score matched analysis from multicenter cohort","volume":"8","author":"Komura","year":"2019","journal-title":"J Clin Med"},{"issue":"5","key":"10.1016\/j.fjurol.2024.102710_bib2130","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1016\/j.eururo.2017.09.022","article-title":"Anticancer activity and tolerance of treatments received beyond progression in men treated upfront with androgen deprivation therapy with or without docetaxel for metastatic castration-na\u00efve prostate cancer in the GETUG-AFU 15 Phase 3 Trial","volume":"73","author":"Lavaud","year":"2018","journal-title":"Eur Urol"},{"issue":"14","key":"10.1016\/j.fjurol.2024.102710_bib2135","doi-asserted-by":"crossref","first-page":"1687","DOI":"10.1200\/JCO.23.02105","article-title":"Efficacy of poly(ADP-ribose) polymerase inhibitors by individual genes in homologous recombination repair gene-mutated metastatic castration-resistant prostate cancer: a US Food and Drug Administration pooled analysis","volume":"42","author":"Fallah","year":"2024","journal-title":"J Clin Oncol"},{"issue":"9747","key":"10.1016\/j.fjurol.2024.102710_bib2140","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1016\/S0140-6736(10)61389-X","article-title":"Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial","volume":"376","author":"de Bono","year":"2010","journal-title":"Lancet"},{"issue":"26","key":"10.1016\/j.fjurol.2024.102710_bib2145","doi-asserted-by":"crossref","first-page":"2506","DOI":"10.1056\/NEJMoa1911206","article-title":"Cabazitaxel versus abiraterone or enzalutamide in metastatic prostate cancer","volume":"381","author":"de Wit","year":"2019","journal-title":"N Engl J Med"},{"issue":"12","key":"10.1016\/j.fjurol.2024.102710_bib2150","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1001\/jamaoncol.2023.4255","article-title":"Biweekly vs. triweekly cabazitaxel in older patients with metastatic castration-resistant prostate cancer: the CABASTY phase 3 randomized clinical trial","volume":"9","author":"Oudard","year":"2023","journal-title":"JAMA Oncol"},{"issue":"10276","key":"10.1016\/j.fjurol.2024.102710_bib2155","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","article-title":"[(177)Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial","volume":"397","author":"Hofman","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.fjurol.2024.102710_bib2160","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S1470-2045(23)00529-6","article-title":"Overall survival with [(177)Lu]Lu-PSMA-617 versus cabazitaxel in metastatic castration-resistant prostate cancer (TheraP): secondary outcomes of a randomised, open-label, phase 2 trial","volume":"25","author":"Hofman","year":"2024","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.fjurol.2024.102710_bib2165","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1016\/j.critrevonc.2017.12.012","article-title":"Loco-regional treatment for castration-resistant prostate cancer: is there any rationale? A critical review from the AFU-GETUG","volume":"122","author":"Beauval","year":"2018","journal-title":"Crit Rev Oncol Hematol"},{"issue":"36","key":"10.1016\/j.fjurol.2024.102710_bib2170","doi-asserted-by":"crossref","first-page":"5561","DOI":"10.1200\/JCO.23.00985","article-title":"Stereotactic body radiation therapy and abiraterone acetate for patients affected by oligometastatic castrate-resistant prostate cancer: a randomized phase II trial (ARTO)","volume":"41","author":"Francolini","year":"2023","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.fjurol.2024.102710_bib2175","doi-asserted-by":"crossref","first-page":"e115060","DOI":"10.1371\/journal.pone.0115060","article-title":"Screening for vulnerability in older cancer patients: the ONCODAGE Prospective Multicenter Cohort Study","volume":"9","author":"Soubeyran","year":"2014","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/j.fjurol.2024.102710_bib2180","doi-asserted-by":"crossref","first-page":"e404","DOI":"10.1016\/S1470-2045(14)70018-X","article-title":"Management of prostate cancer in older patients: updated recommendations of a working grou\/p of the International Society of Geriatric Oncology","volume":"15","author":"Droz","year":"2014","journal-title":"Lancet Oncol"},{"issue":"2","key":"10.1016\/j.fjurol.2024.102710_bib2185","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1200\/JCO.2010.30.2075","article-title":"Impact of age at diagnosis on prostate cancer treatment and survival","volume":"29","author":"Bechis","year":"2011","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.fjurol.2024.102710_bib2190","doi-asserted-by":"crossref","first-page":"2095","DOI":"10.1001\/jama.293.17.2095","article-title":"20-year outcomes following conservative management of clinically localized prostate cancer","volume":"293","author":"Albertsen","year":"2005","journal-title":"JAMA"},{"issue":"5","key":"10.1016\/j.fjurol.2024.102710_bib2195","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/j.eururo.2015.03.021","article-title":"Fifteen-year outcomes following conservative management among men aged 65 years or older with localized prostate cancer","volume":"68","author":"Lu-Yao","year":"2015","journal-title":"Eur Urol"},{"issue":"1","key":"10.1016\/j.fjurol.2024.102710_bib2200","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S1470-2045(13)70546-1","article-title":"Cancer survival in Europe 1999\u20132007 by country and age: results of EUROCARE--5\u00a0\u2013\u00a0a population-based study","volume":"15","author":"De Angelis","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.fjurol.2024.102710_bib2205","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.canep.2018.07.007","article-title":"Incidence of prostate cancer and net survival by grade in a geriatric population: a population-based study in a French administrative entity from 1991 to 2013","volume":"56","author":"Bellier","year":"2018","journal-title":"Cancer Epidemiol"},{"issue":"10","key":"10.1016\/j.fjurol.2024.102710_bib2210","doi-asserted-by":"crossref","first-page":"709","DOI":"10.7326\/0003-4819-158-10-201305210-00005","article-title":"Effect of age, tumor risk, and comorbidity on competing risks for survival in a US population-based cohort of men with prostate cancer","volume":"158","author":"Daskivich","year":"2013","journal-title":"Ann Intern Med"},{"issue":"Suppl. 3","key":"10.1016\/j.fjurol.2024.102710_bib2215","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1111\/bju.14228","article-title":"Localised prostate cancer in elderly men aged 80\u201389 years, findings from a population-based registry","volume":"121","author":"Vatandoust","year":"2018","journal-title":"BJU Int"},{"issue":"1","key":"10.1016\/j.fjurol.2024.102710_bib2220","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.eururo.2014.12.026","article-title":"Undertreatment of men in their seventies with high-risk nonmetastatic prostate cancer","volume":"68","author":"Bratt","year":"2015","journal-title":"Eur Urol"}],"container-title":["The French Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950393024001670?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950393024001670?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,11,21]],"date-time":"2024-11-21T22:59:24Z","timestamp":1732229964000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950393024001670"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11]]},"references-count":245,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["S2950393024001670"],"URL":"https:\/\/doi.org\/10.1016\/j.fjurol.2024.102710","relation":{},"ISSN":["2950-3930"],"issn-type":[{"value":"2950-3930","type":"print"}],"subject":[],"published":{"date-parts":[[2024,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"French AFU Cancer Committee Guidelines\u00a0\u2013\u00a0Update 2024\u20132026: Prostate cancer\u00a0\u2013\u00a0Management of metastatic disease and castration resistance","name":"articletitle","label":"Article Title"},{"value":"The French Journal of Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.fjurol.2024.102710","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"102710"}}